[Morphogenetic bases of an experimental therapy for amyloidosis].
D000042:Absorption; D000682:Amyloid / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology; D000686:Amyloidosis / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D005347:Fibroblasts / Q000502:physiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D051379:Mice; D008810:Mice, Inbred C57BL; D008967:Molecular Biology; D010950:Plasma Cells / Q000502:physiology; D011830:Radiation Effects; D051381:Rats; D013154:Spleen / Q000473:pathology / Q000528:radiation effects / Q000637:transplantation; D013438:Sulfhydryl Compounds / Q000627:therapeutic use
D000682:Amyloid; D000961:Antilymphocyte Serum; D000963:Antimetabolites; D007166:Immunosuppressive Agents; D013438:Sulfhydryl Compounds; D001379:Azathioprine
Morfogeneticheskie osnovy éksperimental'noĭ terapii amiloidoza